
BiolInvent Q1 2025 - Focus on BI-1808 in T-cell Lymphoma

Redeye comments on BiolInvent's first quarter in 2025. After our last update, BI-1808 obtained both Fast Track and Orphan Drug designations from the FDA. It is on track for a phase IIa readout by mid-year. Other programmes, including BI-1206, are also set for important readouts this year. Furthermore, the partnered asset mezagitamab moved into phase III, triggering a milestone payment.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BiolInvent Q1 2025 - Focus on BI-1808 in T-cell Lymphoma